Mr. Kunst has over 20 years of leadership experience in the biopharmaceutical industry, is currently serving as CEO of Valitor and has previously served as CEO of Aurion Biotech and held senior roles at Glaukos Corporation, Alcon, Kinetic Concepts, Inc., and other medical innovation companies.

Linkedin

Mr. Bouckaert is a global biotech executive with over 20 years of experience in strategic consulting and investor strategy, focuses on providing commercial strategic support to small and mid-cap companies. He has supported multiple biotech startups in raising funds and brings trusted access to top-tier investors, KOLs, and life science networks across the U.S. and Europe.

Linkedin

Dr. Goldstein is a seasoned biotechnology executive and corneal specialist with over 25 years of experience in ophthalmology, clinical development, and regulatory strategy. He previously served as President and Chief Medical Officer of Aurion Biotech and held Chief Medical Officere roles at Ocular Therapeutix, AGTC, and Eleven Biotherapeutics. He has helped lead multiple successful FDA interactions and ophthalmic product approvals, including DEXTENZA®. Dr. Goldstein currently serves as Assistant Professor of Ophthalmology at Tufts University School of Medicine. He holds an MD from Northwestern University Feinberg School of Medicine and an MBA from the Kellogg School of Management.

MDMBA

Linkedin

Mr. Fowler is a seasoned financial strategist and U.S. biotech CFO with expertise in capital formation, IPO preparation, and leadership of venture-backed companies. He previously served as VP of Finance at Aurion Biotech, CFO of POSaBIT, a Canadian public company, and has held senior leadership roles across multiple other industries. Mr. Fowler has a strong track record in complex fundraising, financial operations for growth companies, and strategic execution.

MBA

Linkedin

Shinji Uga is President & CEO of CynosBio, where he leads the Company’s global strategy, U.S. expansion, capital markets activities, and international business development initiatives.
Prior to joining CynosBio, Mr. Uga served as a senior executive and CFO at a pioneering advanced medical technology company, where he played a key role in the company’s IPO, global financing transactions, and strategic M&A activities. He also worked as a venture capitalist focused on healthcare and life sciences investments, supporting approximately 30 growth-stage companies.
Since becoming CEO, Mr. Uga has led CynosBio’s transformation into a globally focused regenerative medicine company, expanding U.S. investor engagement, strategic partnerships, and multinational development initiatives.
He is currently leading the Company’s long-term strategy to build a global specialty biopharmaceutical company originating from Japan, focused on regenerative medicine and unmet medical needs.

Linkedin

CPA/MBA

Dr. Yuichi Iwaki is President & CEO of MediciNova, Inc., a NASDAQ-listed biopharmaceutical company focused on innovative therapeutics.
Dr. Iwaki brings more than 30 years of leadership experience spanning biotechnology management, global drug development, and academic medicine. He also serves as a Professor at the University of Southern California School of Medicine.
At CynosBio, Dr. Iwaki contributes strategic oversight in U.S. biotechnology markets, global clinical development, and international corporate governance.

Ken Takanashi is Vice Chairman of Shin Nippon Biomedical Laboratories (SNBL), a leading global CRO and drug development company.
Mr. Takanashi has extensive experience in international business development, U.S. capital markets, and global corporate operations. He played key leadership roles in the NASDAQ listings of Wave Life Sciences and Satsuma Pharmaceuticals and has overseen the establishment and management of more than 40 companies across Japan, the U.S., and Asia.
At CynosBio, he provides strategic guidance on global growth initiatives, U.S. market strategy, and cross-border corporate development.

With over two decades of expertise in the life sciences sector, Shinobu Murakami has successfully spearheaded business development and commercial strategy for innovative therapeutics, medical materials, and advanced regenerative medicines. Her career spans major pharmaceutical enterprises, global healthcare companies, and agile biotechs, including pivotal roles on the leadership team of a global pharmaceutical corporation where she championed strategic growth and corporate execution.
In her role as an Audit and Supervisory Committee Member at CynosBio, she integrates a profound understanding of front-line innovation with rigorous corporate governance, guiding the company toward sustainable value creation through transparent and impactful board oversight.

Kentaro Motoki is an attorney, Certified Public Accountant, and tax advisor with extensive expertise in corporate governance, compliance, accounting, and corporate structuring.
After beginning his career at Deloitte Touche Tohmatsu, Mr. Motoki founded AGRI Law & Accounting Office and has advised numerous growth-stage companies on governance, financing, and organizational strategy.
At CynosBio, he supports the Company’s governance framework, compliance systems, and accountability structure as it expands globally.

Tsuneo Shimoda has extensive experience in healthcare business management, governance, and compliance oversight.
He currently serves as Independent Director (Audit & Supervisory Committee Member) of JMDC Inc., a leading healthcare data and digital health company in Japan.
At CynosBio, he contributes to strengthening governance discipline, operational oversight, and internal control systems as the Company advances its global expansion strategy.